title: Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
abstract: Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings. In this study, we report the identification and biological characterization of X-376 and X-396, two potent and highly specific ALK small molecule tyrosine kinase inhibitors (TKIs). In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clinical trials. Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles. Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein. Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations associated with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant. Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin. Our findings offer preclinical proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.
authors: Departments of Medicine and Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
authors: Christine M
authors: CM
authors: Lovly
authors: Johannes M
authors: JM
authors: Heuckmann
authors: Elisa
authors: E
authors: de Stanchina
authors: Heidi
authors: H
authors: Chen
authors: Roman K
authors: RK
authors: Thomas
authors: Chris
authors: C
authors: Liang
authors: William
authors: W
authors: Pao
references: Cancer Res. 2010 Dec 1;70(23):9827-36
references: 20952506
references: Cell. 2007 Dec 14;131(6):1190-203
references: 18083107
references: Clin Cancer Res. 2008 Jul 1;14(13):4275-83
references: 18594010
references: J Neurooncol. 2010 Sep;99(2):283-6
references: 20146086
references: Am J Pathol. 2000 Aug;157(2):377-84
references: 10934142
references: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22
references: 18089725
references: Oncogene. 2007 Aug 16;26(38):5606-14
references: 17353907
references: Stat Med. 2008 Mar 30;27(7):1040-61
references: 17768754
references: Nat Biotechnol. 2005 Mar;23(3):329-36
references: 15711537
references: Mol Cancer Ther. 2008 Nov;7(11):3499-508
references: 18974395
references: Nature. 2008 Oct 16;455(7215):930-5
references: 18724359
references: Cancer Res. 2008 May 1;68(9):3389-95
references: 18451166
references: Nat Rev Drug Discov. 2004 Dec;3(12):1001-10
references: 15573099
references: Cancer Res. 2007 May 1;67(9):4408-17
references: 17483355
references: Nature. 2008 Oct 16;455(7215):975-8
references: 18923525
references: Nature. 2008 Oct 16;455(7215):971-4
references: 18923524
references: J Biol Chem. 1981 Sep 10;256(17):8878-81
references: 6267054
references: J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94
references: 16106023
references: Adv Enzyme Regul. 1984;22:27-55
references: 6382953
references: Nat Genet. 2009 May;41(5):521-3
references: 19330029
references: N Engl J Med. 2010 Oct 28;363(18):1734-9
references: 20979473
references: J Clin Oncol. 2009 Sep 10;27(26):4232-5
references: 19667260
references: Nature. 2008 Oct 16;455(7215):967-70
references: 18923523
references: Mol Cancer Ther. 2009 Oct;8(10):2811-20
references: 19825801
references: Nat Biotechnol. 2008 Jan;26(1):127-32
references: 18183025
references: Cancer Res. 2008 Jul 1;68(13):4971-6
references: 18593892
references: Nature. 2007 Aug 2;448(7153):561-6
references: 17625570
references: Clin Cancer Res. 2009 May 1;15(9):3143-9
references: 19383809
references: Science. 1994 Mar 4;263(5151):1281-4
references: 8122112
references: Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7
references: 19064915
references: Clin Cancer Res. 2008 Oct 15;14(20):6618-24
references: 18927303
references: Cancer. 2009 Apr 15;115(8):1723-33
references: 19170230
references: Eur J Cancer. 2010 Jul;46(10):1773-80
references: 20418096
references: N Engl J Med. 2010 Oct 28;363(18):1693-703
references: 20979469
references: Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5
references: 17185414
references: J Clin Oncol. 2004 May 1;22(9):1589-97
references: 15117980
references: Cancer Biol Ther. 2007 May;6(5):661-7
references: 17495523
references: PLoS One. 2009;4(2):e4576
references: 19238210
references: Toxicol Appl Pharmacol. 2009 Jun 1;237(2):221-31
references: 19332084